{"id":56390,"date":"2026-02-05T20:07:47","date_gmt":"2026-02-05T12:07:47","guid":{"rendered":"https:\/\/flcube.com\/?p=56390"},"modified":"2026-02-05T20:07:48","modified_gmt":"2026-02-05T12:07:48","slug":"mirxes-partners-with-xtalpi-and-signet-on-ai-driven-gastric-cancer-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56390","title":{"rendered":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System"},"content":{"rendered":"\n<p><strong>Mirxes Singapore<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2629:HKG\">HKG: 2629<\/a>) announced a partnership with <strong>XtalPi Inc.<\/strong> (QuantumPharm, <a href=\"https:\/\/www.google.com\/finance\/quote\/2228:HKG\">HKG: 2228<\/a>) and its incubated company <strong>Signet Therapeutics<\/strong> to establish an <strong>AI-driven precision prevention and treatment system for gastric cancer<\/strong>. The collaboration will create a joint venture in China and Singapore to build a comprehensive &#8220;early screening, diagnosis, and treatment&#8221; closed-loop system within five years.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-partnership-structure-amp-strategic-terms\">Partnership Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Mirxes Singapore \/ XtalPi Inc. (QuantumPharm) \/ Signet Therapeutics<\/td><\/tr><tr><td><strong>Joint Venture<\/strong><\/td><td>To be established in China and Singapore<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Gastric cancer precision prevention and treatment<\/td><\/tr><tr><td><strong>Coverage<\/strong><\/td><td>Early screening, diagnosis, and treatment<\/td><\/tr><tr><td><strong>Technology Stack<\/strong><\/td><td>Mirxes early screening + XtalPi AI drug R&amp;D + Signet targeted drugs<\/td><\/tr><tr><td><strong>Timeline<\/strong><\/td><td>5\u2011year roadmap to build closed\u2011loop system<\/td><\/tr><tr><td><strong>Market Target<\/strong><\/td><td>Asian market expansion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-integration-amp-competitive-advantage\">Technology Integration &amp; Competitive Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mirxes Contribution:<\/strong> Globally leading gastric cancer early screening technology<\/li>\n\n\n\n<li><strong>XtalPi Platform:<\/strong> AI and robotics\u2011powered drug R&amp;D platform for accelerated discovery<\/li>\n\n\n\n<li><strong>Signet Pipeline:<\/strong> World\u2011first targeted drug pipeline for <strong>diffuse gastric cancer<\/strong><\/li>\n\n\n\n<li><strong>Synergistic Value:<\/strong> Combined platform creates end\u2011to\u2011end solution from detection to treatment, addressing unmet need in high\u2011prevalence Asian markets<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Gastric Cancer Burden:<\/strong> Asia accounts for <strong>70%<\/strong> of global gastric cancer cases; China alone sees <strong>480,000<\/strong> new cases annually<\/li>\n\n\n\n<li><strong>AI\u2011Driven Market:<\/strong> Precision oncology market projected to reach <strong>$15\u202fbillion<\/strong> : by 2030; AI\u2011enabled screening and companion diagnostics growing at <strong>25% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate the joint venture could generate <strong>$500\u2013800\u202fmillion<\/strong> : in annual revenue by 2030 across screening, diagnostics, and therapeutics<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> Multi\u2011party collaboration validates Mirxes\u2019 screening platform and XtalPi\u2019s AI capabilities while de\u2011risking Signet\u2019s novel pipeline<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Joint venture formation expected <strong>Q2\u202f2026<\/strong>; first integrated screening\u2011treatment pilot programs to launch in <strong>Tier\u20111 Chinese hospitals<\/strong> by <strong>Q4\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding joint venture formation timelines, market penetration, and revenue projections for the gastric cancer precision system. Actual results may differ due to regulatory approvals, clinical trial outcomes, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,93],"tags":[1112,4245,811,695,221,696],"class_list":["post-56390","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-digital","tag-hkg-2228","tag-hkg-2629","tag-mirxes","tag-quantumpharm","tag-signet-therapeutics","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive &quot;early screening, diagnosis, and treatment&quot; closed-loop system within five years.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56390\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System\" \/>\n<meta property=\"og:description\" content=\"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive &quot;early screening, diagnosis, and treatment&quot; closed-loop system within five years.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56390\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T12:07:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T12:07:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System\",\"datePublished\":\"2026-02-05T12:07:47+00:00\",\"dateModified\":\"2026-02-05T12:07:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390\"},\"wordCount\":335,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2228\",\"HKG: 2629\",\"Mirxes\",\"QuantumPharm\",\"Signet Therapeutics\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56390#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56390\",\"name\":\"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-05T12:07:47+00:00\",\"dateModified\":\"2026-02-05T12:07:48+00:00\",\"description\":\"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive \\\"early screening, diagnosis, and treatment\\\" closed-loop system within five years.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56390\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56390#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System - Insight, China&#039;s Pharmaceutical Industry","description":"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive \"early screening, diagnosis, and treatment\" closed-loop system within five years.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56390","og_locale":"en_US","og_type":"article","og_title":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System","og_description":"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive \"early screening, diagnosis, and treatment\" closed-loop system within five years.","og_url":"https:\/\/flcube.com\/?p=56390","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-05T12:07:47+00:00","article_modified_time":"2026-02-05T12:07:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56390#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56390"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System","datePublished":"2026-02-05T12:07:47+00:00","dateModified":"2026-02-05T12:07:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56390"},"wordCount":335,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2228","HKG: 2629","Mirxes","QuantumPharm","Signet Therapeutics","Xtalpi"],"articleSection":["Company","Deals","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56390#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56390","url":"https:\/\/flcube.com\/?p=56390","name":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-05T12:07:47+00:00","dateModified":"2026-02-05T12:07:48+00:00","description":"Mirxes Singapore (HKG: 2629) announced a partnership with XtalPi Inc. (QuantumPharm, HKG: 2228) and its incubated company Signet Therapeutics to establish an AI-driven precision prevention and treatment system for gastric cancer. The collaboration will create a joint venture in China and Singapore to build a comprehensive \"early screening, diagnosis, and treatment\" closed-loop system within five years.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56390#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56390"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56390#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Mirxes Partners with XtalPi and Signet on AI-Driven Gastric Cancer System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56390"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56390\/revisions"}],"predecessor-version":[{"id":56392,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56390\/revisions\/56392"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}